Full Breakdown
Iovance Biotherapeutics’ Lung-Cancer Trial Results and Their Market Ripple
By Drooid · · How we work
In this breakdown
01
Phase 2 Lung-Cancer Data Release and Immediate Stock Reaction
On October 28 the company announced positive registrational-cohort results from its Phase 2 IOV-LUN-202 trial of lifileucel (Amtagvi) in previously treated nonsquamous metastatic non-small cell lung cancer (NSCLC). The news lifted the shares about 12% in after-hours trading. The following morning, pre-market activity showed an 8.9% decline, later stabilizing to a roughly 6% loss as investors digested the forthcoming webcast details. The trial reported a 24.6% objective response rate (ORR) among 69 patients, with a biomarker-enriched subgroup (KRAS-wild-type, HER2-wild-type, current or former smokers) achieving a 59.1% ORR.
02
Amtagvi Sales Surge and Company Financial Landscape
Amtagvi, the FDA-approved T-cell therapy for advanced melanoma, generated $91 million of Iovance’s $99.3 million total revenue in Q2 2026, a 68% year-over-year increase. Gross margin climbed to 56.1% from 18.5% the prior period, driven by higher Amtagvi volume, cost reductions, and the first full quarter of in-house manufacturing. Operating loss narrowed to $51.9 million from $114 million a year earlier, while free cash flow was -$66.3 million. On September 29, 2026 management raised full-year 2026 revenue guidance to $410 million–$420 million, citing strong U.S. demand for Amtagvi and Proleukin.
Visual evidence
Images from the story
03
Key Numbers at a Glance
Swipe across the table to see all columns.
| Metric | Figure |
|---|---|
| Amtagvi Q2 2026 revenue | $91 M (?68% YoY) |
| Total Q2 2026 revenue | $99.3 M |
| Gross margin (Q2 2026) | 56.1% (up from 18.5%) |
| Operating loss (Q2 2026) | $51.9 M |
| Free cash flow (Q2 2026) | –$66.3 M |
| Lung-cancer ORR (overall) | 24.6% (17/69) |
| Biomarker-enriched subgroup ORR | 59.1% (13/22) |
| KRAS-wild-type ORR | 43.3% vs 11.4% KRAS-mutant |
| Stock move after Oct 28 announcement | +12% after-hours |
| Pre-market move on Oct 29 | –8.9% (later ~-6%) |
04
Management Commentary
- The company also intends to file a supplemental biologics license application for lifileucel in non-squamous NSCLC in 2027.
- Margin discussion: Management attributed the gross-margin improvement to higher Amtagvi volume, cost cuts, and the transition to fully in-house production.
05
Verbatim Quote
- “This level of durability provides meaningful time for patients with refractory UPS and DDLPS suffering from high disease burden, poor quality of life, and a lack of effective treatments, including no approved immunotherapy options,” — Lauren Banks
06
What’s Next
- POSITIVITY cohort enrollment: Starts November 2026, targeting the KRAS-wild-type, HER2-wild-type, smoking-history subgroup.
- Q3 2026 earnings: Expected November 5, will reveal whether quarterly revenue approaches the implied ?$120 million pace and whether gross margin continues to rise.
- Regulatory filings: A supplemental biologics license application for lifileucel in non-squamous NSCLC is slated for 2027, alongside a planned frontline trial (OPTILISM) in the same year.
These developments will determine whether Iovance can translate its expanding Amtagvi sales and promising lung-cancer data into sustained profitability and broader market penetration.